

# Constitutive activity of the human histamine H<sub>4</sub> receptor: Computational studies on wild-type and mutant H<sub>4</sub>R orthologs

David Wifling<sup>1</sup>, Jonas Kaindl<sup>2</sup>, Ralf C. Kling<sup>2</sup>, Armin Buschauer<sup>1</sup>, and Timothy Clark<sup>2</sup>

<sup>1</sup>Institute of Pharmacy, Univ. Regensburg, D-93040 Regensburg


<sup>2</sup>Computer-Chemie-Centrum, Univ. Erlangen-Nürnberg, D-91052 Erlangen

Histamine H<sub>4</sub> receptor (H<sub>4</sub>R) orthologs are G-protein coupled receptors (GPCRs) that exhibit species-dependent constitutive (basal) activity: In contrast to mouse H<sub>4</sub>R (mH<sub>4</sub>R), human H<sub>4</sub>R (hH<sub>4</sub>R) shows a high degree of constitutive activity.

In a previous molecular-pharmacological study, we characterized the constitutive activity of hH<sub>4</sub>R, mH<sub>4</sub>R as well as a series of hH<sub>4</sub>R mutants, comprising hH<sub>4</sub>R-S179M, hH<sub>4</sub>R-F169V, hH<sub>4</sub>R-F169V+S179M [1] and hH<sub>4</sub>R-F168A [2]. An exchange of F169<sup>ECL2</sup> to V significantly decreased the constitutive activity compared to wild-type hH<sub>4</sub>R, while that of the hH<sub>4</sub>R-S179M mutant is similar to that of hH<sub>4</sub>R. [1] Remarkably, the basal activity of the hH<sub>4</sub>R-F169V+S179M [1] and hH<sub>4</sub>R-F168A [2] mutants is even comparable to that of mH<sub>4</sub>R.

Hence, though we identified residues that account for the high constitutive activity of the hH<sub>4</sub>R, the underlying molecular mechanism by which the basal equilibrium between inactive and active receptor states is shifted towards the inactive state is still unknown. To shed light on this matter, we have performed long-time-scale (2  $\mu$ s) molecular-dynamics simulations on wild-type hH<sub>4</sub>R, the hH<sub>4</sub>R mutants S179M, F169V, F169V+S179M, F168A, and on mH<sub>4</sub>R.

During the MD simulations, F169<sup>ECL2</sup> is dipping into the binding pocket merely in case of hH<sub>4</sub>R and is thereby interacting with the surrounding aromatic and hydrophobic residues. Interestingly, F169 seems to take the role of an agonist, thus contributing to the stabilization of the active state. As a measure of binding pocket contraction, the distance ( $C_{\alpha}$ ) between D94<sup>3.32</sup> and Q347<sup>7.42</sup>, starting at approximately 11 Å, increased by a maximum of ~3 Å for the hH<sub>4</sub>R mutants and mH<sub>4</sub>R, while, by contrast, it decreased by up to 3 Å for the basally active hH<sub>4</sub>R. At the intracellular side, initial  $C_{\alpha}$ - $C_{\alpha}$  distances of around 8.0 Å between R112<sup>3.50</sup> and A298<sup>6.30</sup> increased more for hH<sub>4</sub>R than for the hH<sub>4</sub>R mutants and mH<sub>4</sub>R, thus showing an enhanced outward movement of TM6 for hH<sub>4</sub>R compared to the other H<sub>4</sub>R variants. This is in accordance with the fact that GPCR activation is reflected by a subtle contraction of the orthosteric binding pocket and a notable outward motion of TM6 at the intracellular side.



Hence, H<sub>4</sub>R variant-dependent differences between essential motifs of GPCR activation correlate with experimentally determined constitutive activities and provide a molecular explanation for the differences in constitutive activation. Furthermore, the results shed new light on the molecular mechanism of basal H<sub>4</sub>R activation that are of importance for other GPCRs.

[1] D. Wifling, et al., *Br. J. Pharmacol.*, **2015**, 172, 785-798.

[2] D. Wifling, et al., *PLoS One*, **2015**, 10, e0117185.